About Cirrhosis of the Liver
Cirrhosis of the liver (or liver fibrosis) is a serious condition in which the liver stops functioning properly due to damage and irreversible scarring of the liver tissue. The scarring of the tissue is often caused by long-term exposure to viral infections and toxins such as alcohol. Chronic viral hepatitis and non-alcoholic steatohepatitis can also cause liver cirrhosis. Alcohol-related medications, antiviral medications, and metal chelating agents are used in the treatment of the causes of liver cirrhosis while antibiotics, vitamins, corticosteroids, diuretics, beta-blockers, and laxatives are used for the treatment of the complications of the disease.
Technavio’s analysts forecast the global liver cirrhosis therapeutics market to grow at a CAGR of 4.36% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global liver cirrhosis therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of prescription, generic, and off-label drugs used in the treatment of liver cirrhosis.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Liver Cirrhosis Therapeutics Market 2016-2020
Technavio recognizes the following companies as the key players in the global liver cirrhosis therapeutics market: F Hoffman La-Roche, GlaxoSmithKline, Gilead Sciences, Johnson & Johnson, and Merck.
Other Prominent Vendors in the market are: Bristol-Myers Squibb, Conatus Pharmaceuticals, Gwo Xi Stem Cell Applied Technology, Instituto Grifols, Intercept Pharmaceuticals, NGM Biopharmaceuticals, Norgine, Pharmicell, Salix Pharmaceuticals, and Stempeutics Research.
Commenting on the report, an analyst from Technavio’s team said: “A noticeable trend in the market is the use of off-label drugs. Off-label drugs are unapproved medications that are used in the treatment of diseases. For instance, apart from multivitamins and mineral supplements, disulfiram, naltrexone, acamprosate, ciprofloxacin, norfloxacin, ceftriaxone, ofloxacin, amoxicillin-clavulanate, and phytonadione are among the off-label drugs available for the treatment of liver cirrhosis.”
According to the report, a growth driver of this market is the high prevalence of liver cirrhosis. Alcohol has been identified as the strongest risk factor for liver cirrhosis, other than diabetes and hepatitis C, which together constitutes for over 50% of all cirrhosis cases. Relevant health efforts are required to reduce this disease burden, specifically among ethnic minorities and individuals living below the poverty level. As per a studies published, liver cirrhosis affects over 633,000 people every year. It also stated that more than 68% of these individuals may not know that they have the disease, raising the possibility of a large number of undiagnosed cases of liver cirrhosis.
Further, the report states that a challenge that could impact market growth is the adverse effects of drugs used to treat this medical issue.
F Hoffman La-Roche, GlaxoSmithKline, Gilead Sciences, Johnson & Johnson, Merck, Bristol-Myers Squibb, Conatus Pharmaceuticals, Gwo Xi Stem Cell Applied Technology, Instituto Grifols, Intercept Pharmaceuticals, NGM Biopharmaceuticals, Norgine, Pharmicell, Salix Pharmaceuticals, Stempeutics Research.